D. Western Therapeutics Institute, Inc. (4576.T)
JPY 233.0
(14.22%)
JPY 233.0
(14.22%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -586.82 Million | -354.77 Million | -176.3 Million | -216.28 Million | 175 Million |
| Net Income | -826.8 Million | -440.26 Million | -159.71 Million | -289.52 Million | 133 Million |
| Depreciation & Amortization | 48.72 Million | 46.36 Million | 45.25 Million | 44.15 Million | 44 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 15.56 Million | 15.81 Million | 15.22 Million | 9.9 Million | - |
| Change in working capital | 182.74 Million | -81.58 Million | -35.74 Million | 25 Million | 28 Million |
| Other non-cash items | -21.49 Million | 38.65 Million | -17.85 Million | -6.9 Million | -30 Million |
| Investing Cash Flow | -15.25 Million | -139.89 Million | -111.15 Million | -13.46 Million | -100 Million |
| Investments in PPE | -14.93 Million | -9.81 Million | -2.89 Million | -5.12 Million | - |
| Acquisitions | - | - | - | - | -100 Million |
| Investment purchases | - | -130.2 Million | -109.14 Million | -7.86 Million | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | -316 Thousand | 124 Thousand | 897 Thousand | -471 Thousand | -100 Million |
| Financing Cash Flow | 134.46 Million | 867.29 Million | -104.45 Million | 1 Billion | -120 Million |
| Debt repayment | -46 Million | -107 Million | -120 Million | -20 Million | -120 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | -13.51 Million | -1.08 Million | - | - |
| Common Stock Issuance | 88.99 Million | 99.89 Million | 16.62 Million | 1.02 Billion | - |
| Other Financing Activities | -528 Thousand | 887.91 Million | 1000.00 | 808 Thousand | - |
| Accounts receivables | 53 Million | -113 Million | -9 Million | 11 Million | -32 Million |
| Accounts payables | - | - | - | - | -5.05 Million |
| Inventory | 22.59 Million | 9.18 Million | -30.07 Million | 1.04 Million | 106 Thousand |
| Other working capital | 2 Million | 21 Million | -24 Million | 5 Million | 60 Million |
| Cash at beginning of period | 2.33 Billion | 1.93 Billion | 2.3 Billion | 1.54 Billion | 1.58 Billion |
| Cash at end of period | 1.86 Billion | 2.33 Billion | 1.93 Billion | 2.3 Billion | -45 Million |
| Capital Expenditure | -14.93 Million | -9.81 Million | -2.89 Million | -5.12 Million | - |
| Effect of forex changes on cash | 205 Thousand | 28.28 Million | 17.44 Million | -6.95 Million | - |
| Net cash flow / Change in cash | -467.4 Million | 400.92 Million | -374.46 Million | 767.42 Million | -1.62 Billion |
| Free Cash Flow | -601.75 Million | -364.58 Million | -179.2 Million | -221.41 Million | 175 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -320 Million | -369 Million | -826.8 Million | -196 Million | -150 Million | -97 Million |
| Depreciation & Amortization | - | - | 48.72 Million | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | 15.56 Million | - | - | - |
| Change in working capital | - | - | 182.74 Million | - | - | - |
| Other non-cash items | 320 Million | 369 Million | -21.49 Million | 196 Million | 150 Million | 97 Million |
| Investing Cash Flow | - | - | -15.25 Million | - | - | - |
| Investments in PPE | - | - | -14.93 Million | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -316 Thousand | - | - | - |
| Financing Cash Flow | - | - | 134.46 Million | - | - | - |
| Debt repayment | - | - | -46 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 88.99 Million | - | - | - |
| Other Financing Activities | - | - | -528 Thousand | - | - | - |
| Accounts receivables | - | - | 53 Million | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | 22.59 Million | - | - | - |
| Other working capital | - | - | 2 Million | - | - | - |
| Cash at beginning of period | - | - | 2.33 Billion | - | - | - |
| Cash at end of period | - | - | 1.86 Billion | - | - | - |
| Capital Expenditure | - | - | -14.93 Million | - | - | - |
| Effect of forex changes on cash | - | - | 205 Thousand | - | - | - |
| Net cash flow / Change in cash | - | - | -467.4 Million | - | - | - |
| Free Cash Flow | - | - | -601.75 Million | - | - | - |
MORG
BESIY
000503
MCR
3150
300580